We examined our hospital-based occupational health clinic's experience with combination antiretroviral therapy for postexposure prophylaxis for human immunodeficiency virus (HIV).
Over a 12-month period, 68 workers started postexposure prophylaxis : 23 with zidovudine and lamivudine and 45 with zidovudine, lamivudine, and indinavir.
Fifty-one (75%) of the 68 workers starting postexposure prophylaxis reported one or more side effects.
Side effects were more common among those taking three drugs.
Many workers failed to complete the recommended 28-day regimen because of the side effects of the various treatments.
The estimated mean cost for evaluations, prophylaxis, and monitoring of exposed workers was $669 per reported exposure.
In our experience, major challenges in carrying out the current HIV postexposure prophylaxis guidelines include expeditious source testing, improved staff education and prevention measures, and scrupulous monitoring of workers taking combination antiretroviral drugs for postexposure prophylaxis, with consideration of alternate regimens for intolerant workers.
Mots-clés Pascal : Exposition professionnelle, Médecine travail, Equipe soignante, Virus immunodéficience humaine, Lentivirus, Retroviridae, Virus, Chimioprophylaxie, Antiviral, Toxicité, Economie santé, Observance médicamenteuse, Recommandation, Protocole thérapeutique, Homme, Etude cohorte
Mots-clés Pascal anglais : Occupational exposure, Occupational medicine, Health care staff, Human immunodeficiency virus, Lentivirus, Retroviridae, Virus, Chemoprophylaxis, Antiviral, Toxicity, Health economy, Drug compliance, Recommendation, Therapeutic protocol, Human, Cohort study
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0075234
Code Inist : 002B05C02D. Création : 31/05/1999.